TP53 and cancer: Finally, disease-segregating VUS in cancer genes (class 5) provide insights on an additional 7% (1/14) of the TP53 wildtype patients (Supplementary Table S5G), in particular a patient who developed an invasive ductal carcinoma with VUSs in PRF1 and BRD4 (Supplementary Fig. S7D – Patient 2767).